Find Academic Supervisors

• Stem Cell Biology
• Retinal Development
• Ophthalmology
• +3 more

Professor Majlinda Lako is a leading researcher at Newcastle University , specializing in stem cell biology and its applications to ocular diseases. Her work bridges retinal development , genetic disorders , and regenerative medicine , with a focus on patient-derived models. Her research portfolio includes Investigating genotype-phenotype correlations in inherited retinal dystrophies Developing iPSC-derived retinal organoids for drug toxicity screening and therapeutic evaluation Exploring complement system interactions in age-related macular degeneration Advancing 3D culture systems for enhanced retinal tissue development Recent publications highlight her contributions to understanding spliceosome kinetics in retinal disease and optimizing stem cell transplantation protocols. While her specific educational background isn't detailed here, her collaborative work spans multidisciplinary teams in ophthalmology, molecular genetics, and bioinformatics, often intersecting with single-cell transcriptomics and mitochondrial dysfunction studies.

• Bioinformatics
• Artificial Intelligence
• Speech and Signal Processing
• +7 more

Nizamettin Aydın is a Professor in the Department of Computer Engineering at Istanbul Technical University, Faculty of Computer and Informatics. He has previously held academic and administrative positions at Yıldız Technical University, Bahçeşehir University, and Gebze Institute of Technology. His research spans bioinformatics, artificial intelligence, and speech and signal processing, with a focus on wavelet transforms and biomedical applications. PhD, University of Leicester (1990–1994) MS, Yıldız University, Electronics and Communication Engineering (1985–1987) BS, Yıldız University, Electronics and Communication Engineering (1980–1984) His research interests include bioinformatics, artificial intelligence, speech and signal processing, wavelet transforms, and deep learning applications in biomedical and financial domains. He actively applies machine learning and AI techniques to problems in healthcare, such as Alzheimer’s disease and breast cancer analysis, as well as in financial forecasting and NFT systems. The recent publications (2024–2025) reflect a strong trend in interdisciplinary research combining AI with bioinformatics and signal processing. Key areas include embolic signal detection, gene network analysis in cancer, Alzheimer’s biomarker discovery, and financial modeling using deep learning. The use of advanced techniques like transfer learning, ensemble models, and tunable Q-factor wavelet analysis underscores his innovative methodological approach. Scientific awards include: IEE Institution Premium Award (2001) Nizamettin Aydın is an active IEEE member since 1993 and has supervised numerous research projects and publications. He has not received any obituaries or retirement notices, indicating ongoing academic activity. There is no mention of part-time status, and he holds a full professorship. No formal lab or team name is specified, but his collaborative research output suggests leadership in a research group focusing on intelligent signal processing and bioinformatics.

Alessandro D'UrsoView profile

Associate Professor

• Inorganic Chemistry
• Bioinorganic Chemistry
• Supramolecular Chemistry
• +3 more

Alessandro D'Urso is an Associate Professor in Inorganic Chemistry at the Department of Chemical Sciences, University of Catania. His research focuses on the interactions of water-soluble porphyrinoids with biomolecules, particularly DNA/RNA conformations and proteasome activity modulation. Key applications include photodynamic therapy, chiroptical sensing, and supramolecular material design. PhD in Chemistry (2010) from University of Catania Postdoctoral experience at Columbia University (2012) and Barcelona University (2011) Guest editor for special issues on supramolecular systems and porphyrin-biomolecule interactions His work on supramolecular chirality and non-covalent synthesis has led to high-impact publications and grants like PRIN 2017 (€800,000) and FIRB 2012. He explores proteasome inhibition , G-quadruplex stabilization , and chiral nanomaterials . Recent publications (2023-2025) highlight advancements in proteasome allosteric activation , chiroptical DNA probes , and hybrid porphyrin-melanin films . His 60+ papers and H-index of 20 reflect significant citations. Scientific Leadership : Board member of Interdivisional Group of Biotechnologies (2023-2026) Former Vice-coordinator of Italian Chemical Society's Young Group (2013-2016) Reviewer for 20+ journals including Nature Communications and ACS Publications

Bernd GiebelView profile

Professor

• Extracellular Vesicles
• Mesenchymal Stem Cells
• Regenerative Medicine
• +9 more

Prof. Dr. Bernd Giebel is a leading faculty member at the Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen. He leads the Giebel Lab, which is dedicated to advancing the understanding and clinical application of extracellular vesicles (EVs), particularly those derived from mesenchymal stromal cells (MSCs). His research spans hematopoietic progenitor biology and EV-based therapeutics for inflammatory and neurological conditions. His research focuses on elucidating the therapeutic potential of MSC-derived EVs, having demonstrated efficacy in treating graft-versus-host disease and ischemic brain injury. His lab pioneers methods for EV isolation and characterization, including free-flow electrophoresis and imaging flow cytometry. He is deeply involved in standardizing EV research through initiatives like MISEV and EV-TRACK. The recent publications highlight a strong trend toward clinical translation, with work on optimizing EV manufacturing, functional assays, and biomarker discovery. His team investigates EVs in stroke, neuroprotection, immunomodulation, and cancer immunotherapy, often using advanced preclinical models and multi-omics approaches. Founding President, German Society of Extracellular Vesicles (2017–2023) Chair, Exosome Committee, International Society for Cell & Gene Therapy (ISCT) Co-initiator, Mobility for Vesicles in Europe (MOVE) Active member, International Society for Extracellular Vesicles (ISEV) Bernd Giebel mentors several PhD students and postdoctoral researchers, fostering the next generation of EV scientists. His lab collaborates extensively with national and international experts, contributing to influential white papers and consensus guidelines. The research is supported by ongoing projects and publications in top-tier journals, indicating sustained funding and academic leadership. The Giebel Lab operates within the Institute for Transfusion Medicine and is part of the broader research ecosystem at University Hospital Essen, focusing on translational medicine and regenerative therapies.

• Immunometabolism
• Cancer Biology
• Skin Biology
• +6 more

Simon-Pierre Gravel is an Associate Professor at the University of Montreal's Faculté de pharmacie. He holds a PhD in Pharmacy (2011) and completed postdoctoral training at McGill University (2016), focusing on breast cancer metabolism and skin aging. His research investigates the metabolic basis of inflammation in chronic diseases, cancer, and viral infections, with a focus on PGC-1 coactivators' roles in linking cellular metabolism to immune activation. He leads studies on immunometabolism in melanoma and skin aging, supported by grants from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council (NSERC), and the Canadian Cancer Society. Education: PhD in Pharmacy (University of Montreal, 2011), Postdoc at McGill University's Goodman Cancer Research Centre (2016) Research interests include: 1) PGC-1 family proteins' regulation of mitochondrial biology and transcriptional programs, 2) Metabolic drivers of immunosuppression in cancer, 3) Development of therapies targeting metabolism-inflammation axis. His lab has identified stress-induced PGC-1 downregulation as a pro-inflammatory trigger in skin and melanoma contexts. Recent work highlights mitochondrial biogenesis rheostat functions in skin aging and immunometabolic landscapes, with projects funded through NSERC (2023-2029), CIHR (2021-2028), and cancer-focused grants. Over 15 students have been mentored since 2018, including master's theses on PGC-1β modulation and immunotherapy response. Key grants include a 2023 NSERC Discovery Grant for skin aging studies and a 2023 Canadian Cancer Society grant targeting melanoma immunometabolism. He also collaborates on nanoparticle delivery systems for gene therapy and anti-inflammatory drugs. Administrative roles include committee work for the BSc in Biopharmaceutical Sciences program and biosafety oversight. Editor for Metabolites (2019), and peer reviewer for multiple national funding agencies.

Pascale LegaultView profile

Professor

• Molecular Medicine
• Biochemistry
• RNA Structure and Function
• +7 more

Pascale Legault is a Full Professor in the Department of Biochemistry and Molecular Medicine at Université de Montréal, serving as Department Director. Her research focuses on RNA structure and function, particularly non-coding RNAs like ribozymes and microRNAs. She combines structural biology techniques (NMR, X-ray crystallography) with biochemical and bioinformatics approaches to study RNA-protein interactions and their roles in gene regulation and disease. Education: B.Sc. and Ph.D. in Biochemistry from Université de Montréal and University of Colorado Boulder. Postdoctoral work with Nobel laureate Thomas Cech (University of Colorado) and later at the University of Georgia. Joined Université de Montréal in 2003. Research Interests: Structure/function of ribozymes, microRNA biogenesis, RNA engineering, and applications in nanomedicine. Active in structural biology infrastructure development, including leading the Université de Montréal Structural Biology Platform funded by the Canadian Foundation for Innovation (CFI). Awards: Canada Research Chair in RNA Structural Biology, CIHR and FRQS scholarships, and Parkinson Canada funding for miRNA studies in neurodegenerative diseases. Over 70 peer-reviewed publications and several patented methods like ARiBo RNA purification technology. Grants: Multiple CFI, CIHR, and NSERC grants totaling millions, including infrastructure funding for advanced imaging tools. Collaborations with groups like the SNC (Signal Transduction) and GRUM (Drug Research) networks. Labs/Teams: Directs the Pascale Legault Lab, focusing on RNA structural biology and translational applications. Mentored over 20 graduate students/postdocs, including recent PhDs Alix Salvail-Lacoste (2023) and Gunjan Dadhwal (2023).

Michal LinialView profile

Professor

• Neuroscience
• Computational Biology
• Proteomics
• +6 more

Prof. Michal Linial is a Professor at The Hebrew University of Jerusalem, affiliated with the Department of Biological Chemistry and Neuroscience & Computational Biology. Her research focuses on synaptic biology, miRNA regulation, proteomics, and computational biology. She leads a lab conducting interdisciplinary studies combining genomics and proteomics to understand disease mechanisms and molecular functions. Notable contributions include work on cancer genomics, viral evolution, and the role of miRNAs in cellular processes. Recognized as an ICSB 2016 Fellow, her lab collaborates with large-scale databases like TCGA and SFARI. Students under her supervision include Nadav Brandes (PhD) and Roni Rasnic (current). Research interests span bioinformatics methods for protein sequence analysis, viral co-evolution, and miRNA dynamics in health/disease. Her lab’s recent projects explore ER stress responses, microglia in aging brains, and miRNA nuclear localization. Collaborations involve computational tools like ProteinBERT and proteome-wide association studies (PWAS).

Moran YehuView profile

Professor

• Molecular Evolution
• Cnidarian Development
• Animal Venom Evolution
• +3 more

Prof. Moran Yehu is a Professor at the Department of Ecology, Evolution and Behavior at the Hebrew University of Jerusalem, affiliated with the Alexander Silberman Institute of Life Sciences. He leads the Department as its elected head. His research focuses on molecular evolution, particularly in cnidarians, exploring microRNA roles, venom evolution, and antiviral systems. He holds a BSc (Tel Aviv University), MSc (Biochemistry, Tel Aviv University), and PhD (2010, Tel Aviv University), followed by postdoctoral research at the University of Vienna. His lab investigates cnidarian development, toxinology, and RNA pathways, contributing to understanding evolutionary mechanisms in complex systems. Research Interests: - MicroRNA regulation in cnidarian development - Evolution of venom and toxin delivery systems - Antiviral immunity in basal metazoans - Ion channel evolution and function Recipient of the ERC Consolidator Grant (2019) for studying antiviral systems in cnidarians. Leading projects on cnidarian viromes and functional genetics of venom components. Key Achievements: - Characterized venom diversity across life stages in sea anemones. - Discovered novel microRNA functions and evolutionary links with plants. - Elucidated mechanisms of cnidocyte biogenesis using CRISPR/Cas9. Awards: - ERC Consolidator Grant (2019) - Selected Exceeding Article award for Yaara Columbus-Shenkar's work (SMART grant). Lab Activities: - Hosts a multidisciplinary team including postdocs, PhD students, and technicians. - Collaborates internationally on venom evolution and antiviral systems.

Ming ChenView profile

Assistant Professor

• Medical Imaging
• Nanotechnology
• Cancer Research
• +4 more

Ming Chen is an Assistant Professor in the Department of Radiology at Michigan State University. His research focuses on superparamagnetic iron oxide nanoparticles (SPIONs) for medical imaging and targeted drug delivery, alongside investigations into miRNA roles in cancer metastasis and CAR T-cell therapy for solid tumors. Dr. Chen holds a master’s degree in Physics from The University of Hong Kong and a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Dartmouth. He completed postdoctoral training at the Center for Engineering in Medicine at Massachusetts General Hospital/Harvard Medical School. Research Interests Dr. Chen’s work bridges nanotechnology and oncology, emphasizing SPION-based drug delivery systems and molecular mechanisms of cancer metastasis. His lab explores miRNA regulation in glioblastoma progression and develops novel CAR T-cell approaches for solid tumors. This interdisciplinary focus integrates material science, cell biology, and clinical translation toward precision oncology. Article Trends Recent publications highlight advancements in glioblastoma therapeutics using nanodrugs targeting microRNA-10b, synergistic chemotherapy strategies, and foundational studies on electrospun scaffold mechanics. Earlier work includes environmental toxicology studies on alkylphenols and material science innovations for tissue engineering scaffolds. Awards & Grants No scientific awards explicitly listed. Research likely supported through institutional grants and NIH funding given the translational focus of his work. Labs & Collaborations The Chen Lab at MSU Radiology drives interdisciplinary research at the intersection of nanomedicine and cancer biology. Collaborations span clinical institutions like Massachusetts General Hospital and academic labs in biomedical engineering.

Xu PengView profile

Associate Professor

• Cardiovascular Development
• Genetic Mechanisms of Disease
• Molecular Biology
• +4 more

Xu Peng is an Associate Professor in the Department of Medical Physiology at Texas A&M University's School of Medicine. His research focuses on cardiovascular development and disease mechanisms, particularly exploring the role of Cdc42 in vasculogenesis, angiogenesis, and heart development. He leads a lab investigating genetic and molecular pathways involved in cardiovascular conditions such as heart failure and hypertension. Education: Shanghai Tiedao Medical College (MD, 1992), Shanghai Second Medical University (MS, 1997), Peking University (PhD, 2000). Key research areas include: Cdc42 regulation in cardiovascular systems miRNA biogenesis and epigenetic regulation Angiogenesis and lymphatic development Epigenetic mechanisms in heart disease His lab members include Patrick DeSpain (Technician I) and Reed Rivera (Student Research Assistant). Ongoing projects involve mouse genetic models to study Cdc42's role in cardiomyocyte function and vascular integrity. Publications span molecular mechanisms of miRNA regulation, Cdc42's role in embryonic development, and cardiovascular disease pathophysiology. His work bridges basic science and translational medicine to address unmet clinical needs in cardiovascular care.

AntoniouView profile

Professor

• Non-coding RNAs
• Neurological diseases
• Extracellular vesicles (EVs)
• +4 more

Prof. Antoniou is a Professor at the University of Vienna's Faculty of Life Sciences, leading the Molecular Disease Mechanisms group within the Department of Pharmaceutical Sciences. His research focuses on non-coding RNAs (ncRNAs) and extracellular vesicles (EVs) in neurological disorders, particularly their roles in neuronal circuit formation, synaptic plasticity, and therapeutic applications. Key areas include ncRNA secretion via EVs, trans-synaptic EV transmission, and ncRNA contributions to neuropsychiatric susceptibility from early life adversity. He leads multiple grants as Principal Investigator (PI), including DFG-funded projects on BDNF-dependent plasticity and EV-microRNA regulation. Notable awards include the Alexander von Humboldt Postdoctoral Fellowship (2015-2017) and the MRC Centenary Early Career Award (2014-2015). His team includes Postdoc Heba Ali, PhD student Yuzhou Zeng, and MSc researchers Selina Luhmann and Aditi Saha. Research outputs span mechanisms of alpha-synuclein pathology in Parkinson's disease, synaptic mitochondrial regulation via EVs, and miRNA roles in BDNF signaling. His work bridges basic neuroscience with translational nucleic acid therapies for neurological diseases.

Mauro GiaccaView profile

Professor

• Cardiovascular Sciences
• Gene Therapy
• Cardiac Regeneration
• +4 more

Mauro Giacca is the Head of the School of Cardiovascular and Metabolic Medicine & Sciences and Professor of Cardiovascular Sciences at King’s College London. He holds a Medical Degree from the University of Trieste and a PhD in Microbiology and Virology from the University of Genoa. Until 2019, he served as Director-General of the International Centre for Genetic Engineering and Biotechnology (ICGEB), a UN organization in Italy. His research focuses on developing biological therapies for the heart, including gene therapy, cardiac regeneration, and understanding SARS-CoV-2 impacts on cardiovascular systems. Key achievements include founding startups like Forcefield Therapeutics and Heqet Therapeutics, which develop cardiovascular biologics. Giacca is an elected Fellow of the Academy of Medical Sciences and has received prestigious grants like the ERC Advanced Investigator Grant. His work spans over 400 publications, covering viral vectors, RNA therapeutics, and myocardial infarction treatments. He also serves on scientific boards of global institutions and leads initiatives in cardio-oncology and spatial biology. Recent studies include identifying cardioprotective factors via AAV vectors, analyzing SARS-CoV-2’s effect on lung and cardiac tissues, and exploring miRNA roles in heart regeneration. Giacca’s labs investigate mechanisms underlying heart failure, stem cell therapies, and drug delivery innovations. He actively participates in international conferences and editorial roles, emphasizing translational research and clinical application of discoveries.

Ravi SinghView profile

Assistant Professor

• Alternative Splicing
• Molecular Biology
• Genetics
• +5 more

Ravi Singh is an Assistant Professor of Pharmacology at the Department of Pharmacological and Pharmaceutical Sciences , University of Houston College of Pharmacy. His research focuses on molecular mechanisms regulating postnatal cardiac and skeletal muscle growth, contractile function, and metabolic adaptations via alternative splicing.

Curt I. CivinView profile

Professor

• Stem Cell Biology
• Hematopoiesis
• Regenerative Medicine
• +4 more

Curt I. Civin, MD, is the Philip A. Zaffere Distinguished Professor of Regenerative Medicine and Professor of Pediatrics at the University of Maryland School of Medicine. He serves as Director of the Center for Stem Cell Biology & Regenerative Medicine and Associate Dean for Research. His groundbreaking discovery of the CD34 stem cell marker revolutionized hematopoietic stem cell transplantation and leukemia diagnostics. Education BA in Biology/Independent Study, Amherst College (1970, magna cum laude) MD, Harvard Medical School (1974, cum laude) Pediatrics Residency, Boston Children’s Hospital (1974-1976) Fellowships in Pediatric Hematology-Oncology & Tumor-Immunology, NCI/NIH (1976-1979) Research Focus Dr. Civin's research spans stem cell biology, leukemia pathogenesis, and regenerative medicine. He pioneered CD34-based stem cell isolation and investigates microRNA regulation in hematopoiesis. His lab develops novel therapies like artemisinin derivatives for leukemia and microfluidic technologies for cell processing. Current work includes targeting leukemic stem cells via BCL-2/kinase inhibitor combinations and engineering deterministic lateral displacement (DLD) devices for CAR-T cell manufacturing. Publication Trends His recent articles focus on translational applications: optimizing artemisinin-based antileukemic compounds (2021-2023), cardiac progenitor cell mechanisms (2020-2022), and microfluidic innovations for cell therapy (2016-2018). Earlier foundational work defined hematopoietic development and CD34 biology. Awards AAAS Fellow (2022) Karl Landsteiner Memorial Award (2009) National Inventor of the Year (1999) ASH Mentor Award (2015) Mentoring & Grants He mentors physician-scientists and leads NIH/state-funded projects on leukemia stem cells, artemisinin analogs, and bioengineering. Patents include CD34 technologies and microfluidic devices. Laboratory Directs a 40+ year research program studying normal/malignant hematopoiesis using cell lines, primary human cells, and xenograft models. Collaborates with Princeton/GPB Scientific on DLD microfluidics.

• Drug design
• Medicinal chemistry
• Computational chemistry
• +5 more

Roger Estrada Tejedor is a Full Professor at the IQS School of Engineering , Universitat Ramon Llull , where he leads the Pharmaceutical Chemistry Group (GQF) and contributes to both the Unit of Pharmaceutical Chemistry and the Unit of Continuous Chemical Processes . His academic journey includes a PhD in Pharmaceutical Chemistry (2011) from Universitat Ramon Llull, a Master's in Applied Statistics (2013) from UNED, and a Chemical Engineering degree (2006) from IQS. Academic Leadership: Accredited as a Reader by AQU (2015), he became a Full Professor in 2020. Research Focus: Computational drug design, AI-driven pharmaceutical algorithms, and targeting pathogenic RNA structures. Scientific Contributions span dual tyrosine kinase inhibitors for pancreatic cancer, allosteric CXCR4/IRAK4 modulators for lymphoma therapy, and structural simplification strategies in hit discovery. His work bridges molecular modeling with continuous manufacturing optimization, transforming batch chemical systems into efficient, sustainable processes. Collaborative projects include the Franco-Spanish PROTEOblood network addressing proteinopathies in hematological cancers.